Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
Highland began the double-blind, placebo-controlled, U.S. Phase III AHEAD trial to evaluate 40, 60 or 80 mg oral HLD-200 once daily for 3 weeks in about 140 patients ages 6-12. ...